Yesterday Insulet (NASDAQ: PODD) announced they are once again hitting the capital markets. Per a press release;
“Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), a leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced its intention to offer, subject to market and other conditions, $300 million principal amount of convertible senior notes due 2024 (the Notes) in a private placement. Insulet also intends to grant the initial purchasers of the Notes an option to purchase up to an additional $45 million principal amount of Notes.”
Given that by default Insulet is about . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.